National Research/$NRC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About National Research

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

Ticker

$NRC
Sector
Primary listing

Employees

368

NRC Metrics

BasicAdvanced
$374M
20.94
$0.77
0.46
$0.48
2.96%

Bulls say / Bears say

Total recurring contract value increased 2% sequentially in Q2 2025, marking a third consecutive quarter of TRCV growth and the fastest sequential growth rate since Q1 2021. (Business Wire)
Total recurring contract value rose sequentially in Q1 2025, representing a second straight quarter of growth, aided by accelerated sales force expansion. (Business Wire via StockTitan)
Excluding one-time executive compensation expenses, Q2 2025 adjusted EBITDA edged up to $10.3 million, with a 30.3% margin, highlighting disciplined cost controls. (Zacks Equity Research)
Q2 2025 revenue declined 3% year-over-year to $34.0 million, and first-half revenue fell 4%, as subscription services weakened across the client base. (SEC Filing)
Operating income dropped 82% year-over-year in Q2 2025 to $1.6 million, with the company posting a net loss of $0.1 million due to $6.6 million in one-time executive bonuses; operating margin contracted to 5% from 25% the prior year. (SEC Filing)
Total debt rose 68% year-over-year to $81.4 million as of June 30, 2025, increasing net leverage to 3.8× EBITDA—above the 3.5× covenant threshold—raising risks of covenant breaches and higher interest expense. (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

NRC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NRC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Sept26
National Research
DividendEx-dividend
Oct10
National Research
DividendPayment
$0.12Per share
FAQs